Molecular markers as risk factors for thyroid cancer


Cite item

Full Text

Abstract

Thyroid cancer is the most common malignant tumor of the endocrine system. An increase in the incidence of thyroid cancer has been noted over the past decade, mainly due to papillary cancer. The influence of environmental factors, increased availability of medical care, including sensitive diagnostic tests, such as ultrasound and fine - needle aspiration (FNA), can affect the fact of the growth of this incidence. Palpation of thyroid gland has very low diagnostic value for detecting thyroid cancer, while thyroid ultrasound and FNA can detect malignant tumors in 20% of cases. Today, the FNA is the fastest, most accurate, economically accessible, and quite safe method for cytological diagnosis of the thyroid nodules. And molecular genetic testing of FNA samples could serve as an additional reliable diagnostic tool in the case of atypia of undetermined significance.

About the authors

M O Rogova

Sechenov First Moscow State Medical University (Sechenov University)

аспирант каф. эндокринологии лечебного факультета Moscow, Russia

S V Novosad

Sechenov First Moscow State Medical University (Sechenov University)

аспирант каф. эндокринологии лечебного факультета Moscow, Russia

N S Martirosian

Sechenov First Moscow State Medical University (Sechenov University)

Email: narinarine@list.ru
к.м.н., ассистент каф. эндокринологии лечебного факультета; ORCID: 0000-0002-0202-1257 Moscow, Russia

L V Trukhina

Sechenov First Moscow State Medical University (Sechenov University)

к.м.н., доц. каф. эндокринологии лечебного факультета; ORCID: 0000-0001-8997-4984 Moscow, Russia

N A Petunina

Sechenov First Moscow State Medical University (Sechenov University)

д.м.н., проф., зав. каф. эндокринологии лечебного факультета; ORCID: 0000-0001-9390-1200 Moscow, Russia

References

  1. Бельцевич Д.Г., Ванушко В.Э., Мельниченко Г.А., Румянцев П.О., Фадеев В.В. и др. Клинические рекомендации Российской ассоциации эндокринологов по диагностике и лечению (много)узлового зоба у взрослых (2015 год). Эндокринная хирургия. 2016;1(10):5-12. doi: 10.14341/serg201615-12
  2. Noone A.M, Cronin K.A, Altekruse S.F, Howlader N, Lewis D.R, Petkov V.I, Penberthy L. Cancer Incidence and Survival Trends by Subtype Using Data from the Surveillance Epidemiology and End Results Program, 1992-2013. Cancer Epidemiol Biomarkers Prev. 2017 Apr;26(4):632-41. doi: 10.1158/1055-9965.EPI-16-0520
  3. Miki H, Oshimo K, Inoue H, et al. Diagnosis and surgical treatment of small papillary carcinomas of the thyroid gland. J Surg Oncol. 1993 Oct;54(2):78-80; discus. 80-1. doi: 10.1002/jso.2930540204
  4. Nikiforov Y.E. Thyroid tumors: Classification and general considerations. In: Nikiforov Y.E, Biddinger P.W, Thompson L.D.R, eds. Diagnostic pathology and molecular genetcis of the thyroid. Baltimore: Lippincott Williams & Wilkins, 2009. P. 94-102.
  5. Nikiforova M.N, Nikiforov Y.E. Molecular diagnostics and predictors in thyroid cancer. Thyroid. 2009;19(12):1351-61. doi: 10.1089/thy.2009.0240
  6. Cibas E.S, Ali S.Z; NCI Thyroid FNA State of the Science Conference. The Bethesda System For Reporting Thyroid Cytopathology. Am J Clin Pathol. 2009 Nov;132(5):658-65. doi: 10.1309/AJCPPHLWMI3JV4LA
  7. Nikiforov Y.E, Ohori N.P, Hodak S.P, et al. Impact of mutational testing on the diagnosis and management of patients with cytologically indeterminate thyroid nodules: a prospective analysis of 1056 FNA samples. J Clin Endocrinol Metab. 2011;96:3390-7. doi: 10.1210/jc.2011-1469
  8. Haugen B.R, Alexander E.K, Bible K.C, et al. American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016 Jan;26(1):1-133. doi: 10.1089/thy.2015.0020. Review
  9. Nikiforova M.N, Mercurio S, Wald A.I, Barbi de Moura M, Callenberg K, Santana dos Santos L, Gooding W.E, Yip L, Ferris R.L, Nikiforov Y.E. Analytical Performance of the ThyroSeq v3 Genomic Classifier for Cancer Diagnosis in Thyroid Nodules. Cancer. 2018. doi: 10.1002/cncr.31245
  10. Kimura E.T, Nikiforova M.N, Zhu Z, Knauf J.A, Nikiforov Y.E, Fagin J.A. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC - RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res. 2003;63(7):1454-7.
  11. Xing M. BRAF mutation in thyroid cancer. Endocr Relat Cancer. 2005;12(2):245-62. doi: 10.1677/erc.1.0978
  12. Knauf J.A, Ma X, Smith E.P, et al. Targeted expression of BRAFV600E in thyroid cells of transgenic mice results in papillary thyroid cancers that undergo dedifferentiation. Cancer Res. 2005;65(10):4238-45. doi: 10.1158/0008-5472.CAN-05-0047
  13. Namba H, Nakashima M, Hayashi T, et al. Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers. J Clin Endocrinol Metab. 2003;88(9):4393-7. doi: 10.1210/jc.2003-030305
  14. Hou P, Liu D, Shan Y, et al. Genetic alterations and their relationship in the phosphatidylinositol 3-kinase/Akt pathway in thyroid cancer. Clin Cancer Res. 2007;13(4):1161-70. doi: 10.1158/1078-0432.CCR-06-1125
  15. Soares P, Trovisco V, Rocha A.S, et al. BRAF mutations and RET/ PTC rearrangements are alternative events in the etiopathogenesis of PTC. Oncogene. 2003;22(29):4578-80. doi: 10.1038/sj.onc.1206706
  16. Basolo F, Torregrossa L, Giannini R, et al. Correlation between the BRAF V600E mutation and tumor invasiveness in papillary thyroid carcinomas smaller than 20 millimeters: analysis of 1060 cases. J Clin Endocrinol Metab. 2010;95(9):4197-205. doi: 10.1210/jc.2010-0337
  17. Xing M, Westra W.H, Tufano R.P, et al. BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab. 2005;90(12):6373-9. doi: 10.1210/jc.2005-0987
  18. Elisei R, Ugolini C, Viola D, et al. BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow - up study. J Clin Endocrinol Metab. 2008;93(10):3943-9. doi: 10.1210/jc.2008-0607
  19. O’Neill C.J, Bullock M, Chou A, et al. BRAF(V600E) mutation is associated with an increased risk of nodal recurrence requiring reoperative surgery in patients with papillary thyroid cancer. Surgery. 2010;148(6):1139-45, discus. 1145-6. doi: 10.1016/j.surg.2010.09.005
  20. Yip L, Nikiforova M.N, Carty S.E, et al. Optimizing surgical treatment of papillary thyroid carcinoma associated with BRAF mutation. Surgery. 2009;146(6):1215-23. doi: 10.1016/j.surg.2009.09.011
  21. Xing M. Prognostic utility of BRAF mutation in papillary thyroid cancer. Mol Cell Endocrinol. 2010;321(1):86-93. doi: 10.1016/j.mce.2009.10.012
  22. Lee X, Gao M, Ji Y, et al. Analysis of differential BRAF(V600E) mutational status in high aggressive papillary thyroid microcarcinoma. Ann Surg Oncol. 2009;16(2):240-5. doi: 10.1245/s10434-008-0233-3
  23. Xing M. BRAF V600E mutation and papillary thyroid cancer. JAMA. 2013 Aug 7;310(5):535. doi: 10.1001/jama.2013.8592
  24. Esapa C.T, Johnson S.J, Kendall-Taylor P, Lennard T.W, Harris P.E. Prevalence of RAS mutations in thyroid neoplasia. Clin Endocrinol (Oxf). 1999;50(4):529-35. doi: 10.1046/j.1365-2265.1999.00704.x
  25. Basolo F, Pisaturo F, Pollina L.E, et al. N-RAS mutation in poorly differentiated thyroid carcinomas: correlation with bone metastases and inverse correlation to thyroglobulin expression. Thyroid. 2000;10(1):19-23. doi: 10.1089/thy.2000.10.19
  26. Adeniran A.J, Zhu Z, Gandhi M, et al. Correlation between genetic alterations and microscopic features, clinical manifestations, and prognostic characteristics of thyroid papillary carcinomas. Am J Surg Pathol. 2006;30(2):216-2. doi: 10.1097/01.pas.0000176432.73455.1b
  27. Zhu Z, Gandhi M, Nikiforova M.N, Fischer A.H, Nikiforov Y.E. Molecular profile and clinical - pathologic features of the follicular variant of papillary thyroid carcinoma. An unusually high prevalence of RAS mutations. Am J Clin Pathol. 2003;120(1):71-7. doi: 10.1309/nd8d-9laj-trct-g6qd
  28. Powell D.J.Jr, Russell J, Nibu K, et al. The RET/PTC3 oncogene: metastatic solid - type papillary carcinomas in murine thyroids. Cancer Res. 1998;58(23):5523-8.
  29. Tallini G, Santoro M, Helie M, et al. RET/PTC oncogene activation defines a subset of papillary thyroid carcinomas lacking evidence of progression to poorly differentiated or undifferentiated tumor phenotypes. Clin Cancer Res. 1998;4(2):287-94.
  30. Nikiforov Y.E. RET/PTC Rearrangement in Thyroid Tumors. Endocr Pathol. 2002;13(1):3-16. doi: 10.1385/EP:13:1:03
  31. Sugg S.L, Ezzat S, Rosen I.B, Freeman J.L, Asa S.L. Distinct multiple RET/PTC gene rearrangements in multifocal papillary thyroid neoplasia. J Clin Endocrinol Metab. 1998;83(11):4116-22. doi: 10.1210/jcem.83.11.5271
  32. Elisei R, Romei C, Vorontsova T, et al. RET/PTC rearrangements in thyroid nodules: studies in irradiated and not irradiated, malignant and benign thyroid lesions in children and adults J Clin Endocrinol Metab. 2001 Jul;86(7):3211-6. doi: 10.1210/jc.86.7.3211
  33. Saad A, Falciglia M, Steward D.L, Nikiforov Y.E. Amiodarone induced thyrotoxicosis and thyroid cancer: clinical, immunohistochemical, and molecular genetic studies of a case and review of the literature. Arch Pathol Lab Med. 2004;128(7):807-10. doi: 10.1043/1543-2165(2004)128<807:atatcc>2.0.co;2
  34. Mochizuki K, Kondo T, Nakazawa T, et al. RET rearrangements and BRAF mutation in undifferentiated thyroid carcinomas having papillary carcinoma components. Histopathology. 2010;57(3):444-50. doi: 10.1111/j.1365-2559.2010.03646.x
  35. Kroll T.G, Sarraf P, Pecciarini L, et al. PAX8-PPARgamma1 fusion oncogene in human thyroid carcinoma [corrected]. Science. 2000;289(5483):1357-60. doi: 10.1126/science.289.5483.1357
  36. Nikiforova M.N, Lynch R.A, Biddinger P.W, et al. RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma. J Clin Endocrinol Metab. 2003;88(5):2318-26. doi: 10.1210/jc.2002-021907
  37. French C.A, Alexander E.K, Cibas E.S, et al. Genetic and biological subgroups of low - stage follicular thyroid cancer. Am J Pathol. 2003;162(4):1053-60. doi: 10.1016/S0002-9440(10)63902-8
  38. Ohori N.P, Nikiforova M.N, Schoedel K.E, et al. Contribution of molecular testing to thyroid fine - needle aspiration cytology of “follicular lesion of undetermined significance/atypia of undetermined significance”. Cancer Cytopathol. 2010;118(1):17-23. doi: 10.1002/cncy.20063
  39. Liu T, Wang N, Cao J, et al. The age - and shorter telomere - dependent TERT promoter mutation in follicular thyroid cell - derived carcinomas. Oncogene. 2014 Oct 16;33(42):4978-84. doi: 10.1038/onc.2013.446
  40. Xing M, Liu R, Liu X, et al. BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence. J Clin Oncol. 2014 Sep 1;32(25):2718-26. doi: 10.1200/JCO.2014.55.5094
  41. Liu X, Bishop J, Shan Y, Pai S, Liu D, Murugan A.K, Sun H, El Naggar A.K, Xing M. Highly prevalent TERT promoter mutations in aggressive thyroid cancers. Endocr Relat Cancer. 2013;20(4):603-10. doi: 10.1530/ERC-13-0210
  42. Liu X, Qu S, Liu R, Sheng C, Shi X, Zhu G, Murugan A.K, Guan H, Yu H, Wang Y, Sun H, Shan Z, Teng W, Xing M. TERT Promoter mutations and their association with BRAF V600E mutation and aggressive clinicopathological characteristics of thyroid cancer. J Clin Endocrinol Metab. 2014;99(6):1130-6. doi: 10.1210/jc.2013-4048
  43. Vinagre J, Almeida A, Pópulo H, et al. Frequency of TERT promoter mutations in human cancers. Nat Commun. 2013;4:2185. doi: 10.1038/ncomms3185
  44. Melo M, da Rocha A.G, Vinagre J, Batista R, et al. TERT Promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas. J Clin Endocrinol Metab. 2014;99:E754-E765. doi: 10.1210/jc.2013-3734

Copyright (c) 2019 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies